Despite aggressive surgical management, up to 50% of patients with muscle-invasive bladder cancer will have a tumour recurrence, which suggests that a significant proportion of these patients have metastases at the time of diagnosis. Hence, early application of multimodal therapy in bladder cancer is an attractive paradigm, especially to maximize outcomes in patients receiving aggressive local therapy by the immediate treatment of local and distant micrometastatic disease with chemotherapy.

Neoadjuvant chemotherapy

The benefits of using neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer are unclear and as such should not be applied to all patients undergoing radical cystectomy. Most neoadjuvant chemotherapy randomized controlled trials (RCTs) have been underpowered, with significant methodological flaws that have resulted in uniformly poor results with minimal evidence of any improvement in survival. Although most of the neoadjuvant chemotherapy RCTs used cisplatin, drug protocols and combinations were heterogeneous among the trials. The only RCT to show a statistically significant benefit in overall survival was the Nordic 1 trial, which showed a benefit in survival only in cT3/T4a patients undergoing radiotherapy with neoadjuvant doxorubicin and cisplatin. The advantage of this neoadjuvant chemotherapy regimen was not found in patients undergoing radical cystectomy; this was addressed in the Nordic 2 trial.

The touted survival benefits of neoadjuvant chemotherapy are primarily derived from a compilation of 11 RCTs in the form of various meta-analyses, including the Advanced Bladder Cancer Meta-analysis Collaboration (ABC) and the Cancer Care Ontario Meta-analysis. The ABC study, using data from 3005 patients, revealed that the relative benefit of chemotherapy is extremely modest, with a 95% confidence interval (CI) for the hazard ratio (HR) that comes close to 1, and an absolute survival improvement at 5 years of 5% (HR 0.86, 95% CI 0.77–0.95, p = 0.003).

There are many issues with these meta-analyses that need to be addressed. All neoadjuvant chemotherapy meta-analyses included patients with heterogeneous chemotherapy regimens and, most importantly, none included the most popular combination used currently — cisplatin and gemcitabine. The importance of using optimal combination therapies is evident in the fact that in the ABC analysis patients who received single-agent cisplatin actually had worse survival outcomes, compared with surgery alone. There is neither direct evidence for the use of cisplatin and gemcitabine in the neoadjuvant setting nor evidence to suggest the optimal number of cycles of chemotherapy.

Further, all meta-analyses addressing the benefit of neoadjuvant chemotherapy include studies with significant methodological flaws. The ABC study includes data from published and nonpublished trials questioning the quality of the data. The 2 large Nordic studies assessing cisplatin and Adriamycin or methotrexate before cystectomy or radiotherapy included patients who had both neoadjuvant and adjuvant chemotherapy. Other deficiencies of the meta-analyses include the lack of definition of specific tumour or patient characteristics that were predictive of response and, more importantly, inclusion of trials in which most of the patients were younger, had excellent performance status and had good renal function. Hence, the efficacy and safety of neoadjuvant chemotherapy in patients with reduced performance status or other comorbidities is unknown and thus should not be a universally recommended treatment.
Overtreatment with neoadjuvant chemotherapy

Using current standard chemotherapy regimens, neoadjuvant chemotherapy will always be associated with overtreatment; chemotherapy for metastatic bladder cancer produces only a 40%–60% response rate, implying many tumours are inherently chemoresistant and, accordingly, that a significant proportion of localized muscle-invasive tumours will not respond to chemotherapy.

This will obviously delay definitive local therapy in patients who are chemotherapy nonresponders. Using even the best imaging available, assessing tumour response may be difficult to ascertain; CT and MRI imaging is associated with up to a 42% discrepancy between clinical and pathological staging. The potential delay in chemotherapy nonresponders is a fundamental flaw in neoadjuvant chemotherapy since delays to radical cystectomy of greater than 12 weeks have been associated with poor outcomes. In summary, neoadjuvant chemotherapy has rather dubious clinical evidence and should not be recommended for all patients undergoing radical cystectomy.

Advantages of adjuvant chemotherapy

There are many potential advantages of giving chemotherapy in the adjuvant setting, compared with giving chemotherapy before surgery. The primary advantage is that local treatment is not delayed thus minimizing the risk of metastasis during the time from diagnosis to surgery. In addition, the concept of adjuvant chemotherapy allows the chemotherapy treatment to be tailored based on pathological criteria. The ability to risk stratify based on pathological stage is far superior to that of any other preoperative patient or tumour factors and it may prevent the overtreatment of good prognosis patients, such as those with ≤ pT2 disease who can expect up to an 80% 5-year recurrence-free survival. Thus adjuvant therapy allows for optimal timing of surgery and personalization of chemotherapy.

Clinical evidence for adjuvant chemotherapy

Similar to various neoadjuvant RCTs, several adjuvant RCTs have been undertaken (Table 1). However, unlike neoadjuvant trials, many of the adjuvant chemotherapy trials showed statistically significant benefits in survival. Skinner and colleagues randomized 91 patients to receive cisplatin, doxorubicin and cyclophosphamide versus observation after radical cystectomy. Patients receiving chemotherapy had superior time to progression and overall survival. Although criticized for methodological flaws, this study was the first to show the potential benefits of chemotherapy in an adjuvant setting.

Another well-known adjuvant chemotherapy trial is the German MVAC/ MVEC trial lead by Stockle. At 10 years, patients who received adjuvant chemotherapy had significant benefit in both cancer-free survival as well as overall survival; benefits were seen so early that the trial was stopped prematurely. In this study, most patients were high-risk (60% were N+ and most were pT4), pointing out the feasibility and potential benefits of tailoring chemotherapy to risk stratification based on pathology.

### Table 1. Randomized controlled trials of adjuvant chemotherapy in patients with muscle invasive bladder cancer

<table>
<thead>
<tr>
<th>Study</th>
<th>Chemotherapy drugs</th>
<th>Group; no. of patients</th>
<th>Benefit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skinner et al.</td>
<td>CAP</td>
<td>47/44</td>
<td>3 yr DFS: 70% v. 46%; median survival: 4.3 yr v. 2.4 yr; p = 0.006</td>
</tr>
<tr>
<td>Lehmann et al.</td>
<td>MV(A/E)C</td>
<td>26/23</td>
<td>10 yr DFS: 41.7% v. 17.4%; 10 yr OS: 41.7% v. 17.4%</td>
</tr>
<tr>
<td>Studer et al.</td>
<td>Cisplatin</td>
<td>40/37</td>
<td>No benefit; OS: 54% v. 57%</td>
</tr>
<tr>
<td>Freiha et al.</td>
<td>CMV</td>
<td>25/25</td>
<td>Benefit; DFS:50% v. 22%; p = 0.01; OS: 54% v. 34% at 5 yr, NS</td>
</tr>
</tbody>
</table>

CAP = cyclophosphamide, doxorubicin cisplatin; CMV = cisplatin, methotrexate and vinblastine; DFS = disease-free survival; OS = overall survival; MV(A/E)C = methotrexate, vinblastine, doxorubicin or epirubicin, and cisplatin.
pathology. However, this study has been criticized, primarily for its small sample size, which was owing to its early discontinuation, as well as the fact that most patients with recurrences in the observation arm did not receive chemotherapy.

Freiha and colleagues compared patients with pT3 and pT4 bladder cancers treated with or without cisplatin, methotrexate and vinblastine. Like the Stockle study, the Freiha study was discontinued early owing to the benefit found at interim analysis of patients receiving adjuvant chemotherapy. Time to progression was longer in patients who received chemotherapy (37 v. 12 mo, \( p = 0.01\)) at a median 62 months follow-up. The study was not powered to detect survival advantages.

A recent meta-analysis assessing adjuvant chemotherapy from 6 RCTs with a total of 491 patients showed that there was a 9% improvement in absolute survival at 3 years (HR 0.75, 95% CI 0.60–0.96, \( p = 0.019\)). However, the authors point out that the sample sizes for all of the studies were too underpowered and the results not “conclusive” enough to recommend adjuvant chemotherapy without more clinical evidence. In summary, although methodologically imperfect and not powered to determine overall survival differences, these RCTs show that adjuvant chemotherapy is feasible and safe, and, most importantly, that it may prolong cancer-free survival.

### Summary

Based on all currently available clinical data, neoadjuvant chemotherapy is associated with significant overtreatment, flawed clinical trials as well as the lack of consensus of a chemotherapeutic protocol. Adjuvant therapy appears to be a more attractive concept, with many advantages and evidence of the benefit of time to cancer-free survival.

Assistant Professor, Department of Urologic Sciences, University of British Columbia, Vancouver, BC

The positions provided in the Point/Counterpoint series are presented as general information and do not necessarily reflect the personal opinions of the authors.

This article has been peer reviewed.

Competing interests: None declared.

### References


